MBI’s Oralex finishes phase II trials

Article

Ultrasound contrast agent developer Molecular Biosystems has completed phase II clinical trials of its Oralex oral ultrasound contrast agent, which is targeted for the improvement of abdominal ultrasound images. Preliminary data evaluation of the

Ultrasound contrast agent developer Molecular Biosystems has completed phase II clinical trials of its Oralex oral ultrasound contrast agent, which is targeted for the improvement of abdominal ultrasound images. Preliminary data evaluation of the 59-patient study found that Oralex provided significant diagnostic utility when compared with noncontrast and water-contrast imaging, according to MBI.

Oralex works by distending the stomach and displacing bowel gas to provide physicians with a better view of the upper gastrointestinal anatomy, including the stomach wall and pancreas. The San Diego-based firm believes that Oralex provides significant benefit over the current method of improving ultrasound images, which involves ingestion of water.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.